To study the association of long-term statin use and the risk of low-energy hip fractures in middle-aged and elderly women.A register-based cohort study.Finland.Women aged 45–75 years initiating statin therapy between 1996 and 2001 with adherence to statins ≥80% during the subsequent five years (n = 40 254), a respective cohort initiating hypertension drugs (n = 41 610), and women randomly selected from the population (n = 62 585).Incidence rate of and hazard ratio (HR) for low-energy hip fracture during the follow-up extending up to 7 years after the 5-year exposure period.Altogether 199 low-energy hip fractures occurred during the 135 330 person-years (py) of follow-up in the statin cohort, giving an incidence rate of 1.5 hip fractures pe...
Objective: The aim of this study was to assess the mortality in hip fracture patients with regard to...
Background Recent data suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (stat...
We report the risks of a comprehensive range of disease and drug categories on hip fracture occurren...
To study the association of long-term statin use and the risk of low-energy hip fractures in middle-...
BACKGROUND: Inhibitors of hydroxymethylglutaryl-coenzyme A reductase (statins) increase new bone for...
Background3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to st...
PURPOSE: Conflicting findings were observed from clinical trials and observational studies evaluatin...
Context Previous studies have reported lower fracture risks in patients taking 3-hydroxy-3-methylglu...
*<p>8 persons missing data on region of residence excluded.</p><p>HR = Hazard ratio.</p>†<p>Age, cor...
Background: Many people with a high risk of hip fracture have coexisting cardiovascular diseases. We...
Objective: Experimental findings and previous observational data have suggested lower risk of osteoa...
A positive history of fractures in older patients with hip fracture is common. We determined the ris...
Background: Risk factors for hip fracture are well studied because of the negative impact on patient...
BACKGROUND:Osteoporosis, together with age, is the main risk factor for hip fracture, the incidence ...
Study Objective. To ascertain the relationship between warfarin therapy and subsequent hip fracture ...
Objective: The aim of this study was to assess the mortality in hip fracture patients with regard to...
Background Recent data suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (stat...
We report the risks of a comprehensive range of disease and drug categories on hip fracture occurren...
To study the association of long-term statin use and the risk of low-energy hip fractures in middle-...
BACKGROUND: Inhibitors of hydroxymethylglutaryl-coenzyme A reductase (statins) increase new bone for...
Background3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to st...
PURPOSE: Conflicting findings were observed from clinical trials and observational studies evaluatin...
Context Previous studies have reported lower fracture risks in patients taking 3-hydroxy-3-methylglu...
*<p>8 persons missing data on region of residence excluded.</p><p>HR = Hazard ratio.</p>†<p>Age, cor...
Background: Many people with a high risk of hip fracture have coexisting cardiovascular diseases. We...
Objective: Experimental findings and previous observational data have suggested lower risk of osteoa...
A positive history of fractures in older patients with hip fracture is common. We determined the ris...
Background: Risk factors for hip fracture are well studied because of the negative impact on patient...
BACKGROUND:Osteoporosis, together with age, is the main risk factor for hip fracture, the incidence ...
Study Objective. To ascertain the relationship between warfarin therapy and subsequent hip fracture ...
Objective: The aim of this study was to assess the mortality in hip fracture patients with regard to...
Background Recent data suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (stat...
We report the risks of a comprehensive range of disease and drug categories on hip fracture occurren...